LatentRx — Drug Repurposing Intelligence Platform

Resurrecting Shelved Drugs Through Post-Clinical Signal Mining

LatentRx mines three decades of FDA adverse event reports, off-label prescription patterns, and post-marketing surveillance data to identify hidden therapeutic potential in approved compounds that the industry has overlooked.

What Is Drug Repurposing?

The pharmaceutical industry spends an average of $2 billion and 10–15 years bringing a single new molecule from discovery to approval. Meanwhile, thousands of approved drugs sit on the shelf — their post-marketing data revealing therapeutic signals that were never pursued. LatentRx systematically mines that data.

FAERS Signal Mining

We analyze millions of FDA Adverse Event Reporting System records to detect unexpected beneficial outcomes — signals that suggest a drug may treat conditions it was never designed for.

AI-Powered SAR Analysis

Structure-Activity Relationship mapping powered by AI identifies mechanistic pathways between a compound's molecular structure and its observed clinical effects, surfacing repurposing candidates with biological plausibility.

505(b)(2) Pathway Strategy

Each repurposing lead includes a regulatory strategy assessment for the FDA's 505(b)(2) pathway — the fastest route to approval for drugs with existing safety data, cutting development time by 40–60%.

How LatentRx Works

Our platform transforms raw post-marketing data into actionable drug development intelligence through a four-stage pipeline.

1. Ingest — We pull FAERS adverse event data, off-label prescribing patterns, and clinical literature for every compound in our database.
2. Analyze — AI models cross-reference adverse events with known mechanisms, identifying disproportionate beneficial signal clusters.
3. Score — Each repurposing lead receives a composite confidence score based on clinical evidence, mechanistic plausibility, and regulatory feasibility.
4. Deliver — Pharmacists and researchers access structured intelligence — tiered leads, risk profiles, CYP interaction data, and MTM billing opportunities.

Acarbose: From Diabetes Drug to Longevity Candidate

Acarbose, an alpha-glucosidase inhibitor approved in 1995 for Type 2 diabetes, was progressively shelved due to gastrointestinal side effects. Our signal mining uncovered three viable repurposing pathways — including a Tier I longevity lead with a 92% composite confidence score.

• ITP-validated preclinical lifespan extension data
• Coherent mTORC1 suppression mechanism identified
• FGF21 upregulation via colonic fermentation pathways
• Cardiovascular risk reduction (Tier II confidence)
• Neuroprotective effects via gut-brain axis (Tier III confidence)

Built for Drug Repurposing Stakeholders

Clinical Pharmacists

Identify MTM billing opportunities, monitor off-label signals for patients, and contribute pharmacovigilance data through our submission portal. NPI-verified access ensures professional credentialing.

Drug Development Teams

Access structured 505(b)(2) intelligence with composite confidence scores, mechanistic SAR data, and regulatory pathway assessments for every repurposing lead in our database.

Research Institutions

Leverage our FAERS signal mining pipeline and AI research assistant to accelerate hypothesis generation for translational studies and clinical trial design.

Get in Touch

Have questions about drug repurposing intelligence, partnership opportunities, or platform access? We'd love to hear from you.